健康元(600380.SH):子公司麗珠集團擬7.24億元受讓天津同仁堂40%股份
格隆匯3月22日丨健康元(600380.SH)公佈,公司控股子公司麗珠集團將使用自有資金人民幣7.24億元受讓天津天士力所持有的天津同仁堂4400萬股股份,佔天津同仁堂股份總數的40.00%。
天津同仁堂經營業績穩健,產品獨特且有良好的發展潛力。2021年3月9日,天津證監局已公示接受其首次公開發行股票(並在深圳證券交易所創業板上市)(以下簡稱:IPO)的輔導申請。交易完成後,麗珠集團不僅可在中藥業務發展方面與天津同仁堂進行一定的協同,而且還可以通過其現金分紅或首次公開募股上市等方式實現相應的投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.